244 related articles for article (PubMed ID: 26098886)
1. Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.
Carson C; Raman P; Tullai J; Xu L; Henault M; Thomas E; Yeola S; Lao J; McPate M; Verkuyl JM; Marsh G; Sarber J; Amaral A; Bailey S; Lubicka D; Pham H; Miranda N; Ding J; Tang HM; Ju H; Tranter P; Ji N; Krastel P; Jain RK; Schumacher AM; Loureiro JJ; George E; Berellini G; Ross NT; Bushell SM; Erdemli G; Solomon JM
PLoS One; 2015; 10(6):e0127498. PubMed ID: 26098886
[TBL] [Abstract][Full Text] [Related]
2. (-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels.
Akbulut Y; Gaunt HJ; Muraki K; Ludlow MJ; Amer MS; Bruns A; Vasudev NS; Radtke L; Willot M; Hahn S; Seitz T; Ziegler S; Christmann M; Beech DJ; Waldmann H
Angew Chem Int Ed Engl; 2015 Mar; 54(12):3787-91. PubMed ID: 25707820
[TBL] [Abstract][Full Text] [Related]
3. Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.
Rubaiy HN; Seitz T; Hahn S; Choidas A; Habenberger P; Klebl B; Dinkel K; Nussbaumer P; Waldmann H; Christmann M; Beech DJ
Br J Pharmacol; 2018 Mar; 175(5):830-839. PubMed ID: 29247460
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.
Grant CV; Carver CM; Hastings SD; Ramachandran K; Muniswamy M; Risinger AL; Beutler JA; Mooberry SL
Breast Cancer Res Treat; 2019 Sep; 177(2):345-355. PubMed ID: 31230251
[TBL] [Abstract][Full Text] [Related]
5. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels.
Miller M; Shi J; Zhu Y; Kustov M; Tian JB; Stevens A; Wu M; Xu J; Long S; Yang P; Zholos AV; Salovich JM; Weaver CD; Hopkins CR; Lindsley CW; McManus O; Li M; Zhu MX
J Biol Chem; 2011 Sep; 286(38):33436-46. PubMed ID: 21795696
[TBL] [Abstract][Full Text] [Related]
6. Shape Similarity by Fractal Dimensionality: An Application in the de novo Design of (-)-Englerin A Mimetics.
Friedrich L; Byrne R; Treder A; Singh I; Bauer C; Gudermann T; Mederos Y Schnitzler M; Storch U; Schneider G
ChemMedChem; 2020 Apr; 15(7):566-570. PubMed ID: 32162837
[TBL] [Abstract][Full Text] [Related]
7. Na
Muraki K; Ohnishi K; Takezawa A; Suzuki H; Hatano N; Muraki Y; Hamzah N; Foster R; Waldmann H; Nussbaumer P; Christmann M; Bon RS; Beech DJ
Sci Rep; 2017 Dec; 7(1):16988. PubMed ID: 29209034
[TBL] [Abstract][Full Text] [Related]
8. Tonantzitlolone is a nanomolar potency activator of transient receptor potential canonical 1/4/5 channels.
Rubaiy HN; Ludlow MJ; Siems K; Norman K; Foster R; Wolf D; Beutler JA; Beech DJ
Br J Pharmacol; 2018 Aug; 175(16):3361-3368. PubMed ID: 29859013
[TBL] [Abstract][Full Text] [Related]
9. (-)-Englerin A-evoked Cytotoxicity Is Mediated by Na+ Influx and Counteracted by Na+/K+-ATPase.
Ludlow MJ; Gaunt HJ; Rubaiy HN; Musialowski KE; Blythe NM; Vasudev NS; Muraki K; Beech DJ
J Biol Chem; 2017 Jan; 292(2):723-731. PubMed ID: 27875305
[TBL] [Abstract][Full Text] [Related]
10. (-)-Englerin-A Has Analgesic and Anti-Inflammatory Effects Independent of TRPC4 and 5.
de Sousa Valente J; Alawi KM; Bharde S; Zarban AA; Kodji X; Thapa D; Argunhan F; Barrett B; Nagy I; Brain SD
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203675
[TBL] [Abstract][Full Text] [Related]
11. TRPC5 Does Not Cause or Aggravate Glomerular Disease.
Wang X; Dande RR; Yu H; Samelko B; Miller RE; Altintas MM; Reiser J
J Am Soc Nephrol; 2018 Feb; 29(2):409-415. PubMed ID: 29061651
[TBL] [Abstract][Full Text] [Related]
12. Potent, selective, and subunit-dependent activation of TRPC5 channels by a xanthine derivative.
Minard A; Bauer CC; Chuntharpursat-Bon E; Pickles IB; Wright DJ; Ludlow MJ; Burnham MP; Warriner SL; Beech DJ; Muraki K; Bon RS
Br J Pharmacol; 2019 Oct; 176(20):3924-3938. PubMed ID: 31277085
[TBL] [Abstract][Full Text] [Related]
13. Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels.
Zhu Y; Lu Y; Qu C; Miller M; Tian J; Thakur DP; Zhu J; Deng Z; Hu X; Wu M; McManus OB; Li M; Hong X; Zhu MX; Luo HR
Br J Pharmacol; 2015 Jul; 172(14):3495-509. PubMed ID: 25816897
[TBL] [Abstract][Full Text] [Related]
14. Englerin a selectively induces necrosis in human renal cancer cells.
Sulzmaier FJ; Li Z; Nakashige ML; Fash DM; Chain WJ; Ramos JW
PLoS One; 2012; 7(10):e48032. PubMed ID: 23144724
[TBL] [Abstract][Full Text] [Related]
15. Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels.
Jiang H; Zeng B; Chen GL; Bot D; Eastmond S; Elsenussi SE; Atkin SL; Boa AN; Xu SZ
Biochem Pharmacol; 2012 Apr; 83(7):923-31. PubMed ID: 22285229
[TBL] [Abstract][Full Text] [Related]
16. Pico145 - powerful new tool for TRPC1/4/5 channels.
Rubaiy HN; Ludlow MJ; Bon RS; Beech DJ
Channels (Austin); 2017 Sep; 11(5):362-364. PubMed ID: 28399685
[No Abstract] [Full Text] [Related]
17. Activation of TRPC cationic channels by mercurial compounds confers the cytotoxicity of mercury exposure.
Xu SZ; Zeng B; Daskoulidou N; Chen GL; Atkin SL; Lukhele B
Toxicol Sci; 2012 Jan; 125(1):56-68. PubMed ID: 21984481
[TBL] [Abstract][Full Text] [Related]
18. Englerin A Inhibits T-Type Voltage-Gated Calcium Channels at Low Micromolar Concentrations.
Wardas B; Schneider JG; Klugbauer N; Flockerzi V; Beck A
Mol Pharmacol; 2023 Oct; 104(4):144-153. PubMed ID: 37399325
[TBL] [Abstract][Full Text] [Related]
19. TRPC4- and TRPC4-containing channels.
Freichel M; Tsvilovskyy V; Camacho-Londoño JE
Handb Exp Pharmacol; 2014; 222():85-128. PubMed ID: 24756704
[TBL] [Abstract][Full Text] [Related]
20. Total synthesis of englerin A.
Nicolaou KC; Kang Q; Ng SY; Chen DY
J Am Chem Soc; 2010 Jun; 132(23):8219-22. PubMed ID: 20496885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
